NASDAQ: TCBPTc Biopharm PLC Stock
$0.43+0.01 (+2.38%)
Updated Sep 29, 2023
TCBP Price
$0.43
Fair Value Price
N/A
Market Cap
$971.80k
52 Week Low
$0.35
52 Week High
$14.50
P/E
-0.17x
P/B
-30.28x
P/S
0.66x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.81M
Earnings
-$1.67M
Gross Margin
100%
Operating Margin
101.05%
Profit Margin
-36.1%
Debt to Equity
-427.48
Operating Cash Flow
-$19M
Beta
1.53
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TCBP Overview
TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia, and ImmuniStim, an unmodified cell therapy to treat COVID-19. TC Biopharm was founded in 2013 and is headquartered in Motherwell, UK.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TCBP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TCBP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TCBP is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
TCBP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more TCBP due diligence checks available for Premium users.
Be the first to know about important TCBP news, forecast changes, insider trades & much more!
TCBP News
Valuation
TCBP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.17x
Industry
13.67x
Market
12.37x
TCBP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-30.28x
Industry
5.09x
TCBP's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
TCBP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TCBP's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$13.2M
Liabilities
$13.2M
Debt to equity
-427.48
TCBP's short-term liabilities ($11.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TCBP's short-term assets ($9.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TCBP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TCBP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
TCBP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TCBP vs Biotech Stocks
Tc Biopharm Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.